{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:30Z","timestamp":1786119930093,"version":"build-2736575974"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/rlu.0b013e318224b814","type":"journal-article","created":{"date-parts":[[2011,6,29]],"date-time":"2011-06-29T07:37:08Z","timestamp":1309333028000},"page":"e72-e80","source":"Crossref","is-referenced-by-count":6,"title":["ACR\u2013ASTRO Practice Guideline for the Performance of Therapy With Unsealed Radiopharmaceutical Sources"],"prefix":"10.1097","volume":"36","author":[{"given":"Robert E.","family":"Henkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Del Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry W.","family":"Grigsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Hartford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Jadvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Macklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Anthony","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Y. C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210204","first-page":"1203","article-title":"ACR technical standard for diagnostic procedures using radiopharmaceuticals. Practice Guidelines and Technical Standards.","year":"2008"},{"key":"R4-12-20210204","first-page":"1003","article-title":"Practice guideline for radioembolization with microsphere brachytherapy device (RMBD) for treatment of liver malignancies. Practice Guideline and Technical Standards.","year":"2008"},{"key":"R5-12-20210204","first-page":"923","article-title":"ACR practice guideline for radiation oncology. Practice Guidelines and Technical Standards.","year":"2008"},{"key":"R6-12-20210204","first-page":"937","article-title":"ACR practice guideline on informed consent\u2014radiation oncology. Practice Guidelines and Technical Standards.","year":"2008"},{"key":"R9-12-20210204","first-page":"845","article-title":"ACR practice guideline for the performance of thyroid scintigraphy and uptake measurements. Practice Guidelines and Technical Standards.","year":"2008"},{"key":"R10-12-20210204","first-page":"261","article-title":"Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?","volume":"46","author":"Nakada","year":"2005","journal-title":"J Nucl Med"},{"key":"R11-12-20210204","first-page":"380","article-title":"Autopsy of a cadaver containing strontium-89-chloride.","volume":"38","author":"Schraml","year":"1997","journal-title":"J Nucl Med"},{"key":"R12-12-20210204","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/cbr.2006.21.101","article-title":"Extravasation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case report.","volume":"21","author":"Williams","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"R13-12-20210204","first-page":"863","article-title":"ACR practice guideline for the performance of gastrointestinal scintigraphy. Practice Guidelines and Technical Standards.","year":"2008"},{"key":"R14-12-20210204","first-page":"931","article-title":"ACR practice guideline for communication: radiation oncology. Practice Guidelines and Technical Standards.","year":"2008"},{"key":"R1A1-12-20210204","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0090-8258(85)90266-5","article-title":"Complications from intraperitoneal radioactive phosphorus in ovarian malignancies.","volume":"21","author":"Bakri","year":"1985","journal-title":"Gynecol Oncol"},{"key":"R2A1-12-20210204","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1210\/jc.2003-030298","article-title":"Radioiodine treatment with 30 mCi after recombinant effectiveness for postsurgical remnants ablation.","volume":"88","author":"Barbaro","year":"2003","journal-title":"J Endocrinol Metab"},{"key":"R3A1-12-20210204","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0360-3016(97)00927-9","article-title":"Radiotherapeutic management of osseous metastases: a survey of current patterns of care.","volume":"40","author":"Ben-Josef","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R4A1-12-20210204","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF03343960","article-title":"Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid stimulating hormone.","volume":"25","author":"Berg","year":"2002","journal-title":"J Endocrinol Invest"},{"key":"R6A1-12-20210204","first-page":"79","article-title":"Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.","volume":"2","author":"Brundage","year":"1998","journal-title":"Cancer Prev Control"},{"key":"R7A1-12-20210204","first-page":"206","article-title":"Radiation safety when a patient dies after therapy.","volume":"26","author":"Bybel","year":"1998","journal-title":"J Nucl Med Technol"},{"key":"R8A1-12-20210204","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/jcem.85.1.6310","article-title":"Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?","volume":"85","author":"Cailleux","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R9A1-12-20210204","first-page":"1198","article-title":"Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.","volume":"41","author":"Cholewinski","year":"2000","journal-title":"J Nucl Med"},{"key":"R10A1-12-20210204","first-page":"1868","article-title":"Therapeutic I-131 in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.","volume":"41","author":"Coover","year":"2000","journal-title":"J Nucl Med"},{"key":"R11A1-12-20210204","first-page":"1402","article-title":"Radiation safety considerations for post-Iodine-131 thyroid cancer therapy.","volume":"33","author":"Culver","year":"1992","journal-title":"J Nucl Med"},{"key":"R12A1-12-20210204","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0090-8258(81)90149-9","article-title":"Radioactive chromic phosphate suspension: studies on distribution, dose absorption, and effective therapeutic radiation in phantoms, dogs, and patients.","volume":"12","author":"Currie","year":"1981","journal-title":"Gynecol Oncol"},{"key":"R13A1-12-20210204","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1001\/jama.283.17.2272","article-title":"Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma.","volume":"283","author":"Grigsby","year":"2000","journal-title":"JAMA"},{"key":"R14A1-12-20210204","first-page":"567","article-title":"Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1\u20133 weeks of thyroxine discontinuation.","volume":"45","author":"Grigsby","year":"2004","journal-title":"J Nucl Med"},{"key":"R15A1-12-20210204","article-title":"Nuclear Medicine Therapy.","author":"Harbert","year":"1987"},{"key":"R16A1-12-20210204","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJM199805143382007","article-title":"Treatment of benign nodular thyroid disease.","volume":"338","author":"Hermus","year":"1998","journal-title":"N Engl J Med"},{"key":"R17A1-12-20210204","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1628::AID-CNCR13>3.0.CO;2-1","article-title":"Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals.","volume":"80","author":"Janjan","year":"1997","journal-title":"Cancer"},{"key":"R18A1-12-20210204","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s002770050576","article-title":"Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience.","volume":"79","author":"Johnson","year":"2000","journal-title":"Ann Hematol"},{"key":"R19A1-12-20210204","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"R20A1-12-20210204","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.1988.6.8.1254","article-title":"Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trails Group report.","volume":"6","author":"Klassen","year":"1988","journal-title":"J Clin Oncol"},{"key":"R21A1-12-20210204","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.","volume":"2","author":"Knox","year":"1996","journal-title":"Clin Cancer Res"},{"key":"R22A1-12-20210204","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s002590000315","article-title":"Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement.","volume":"27","author":"Kraeber-Bodere","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"R23A1-12-20210204","first-page":"594","article-title":"Nuclear Medicine.","volume":"1","author":"Kuzel","year":"1996"},{"key":"R24A1-12-20210204","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jc.2002-020805","article-title":"A randomized comparison of raidoiodine doses in Graves' hyperthyroidism.","volume":"88","author":"Leslie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R25A1-12-20210204","first-page":"74","article-title":"Pediatric thyroid nodules: insights in management.","volume":"90","author":"Lugo-Vicente","year":"1998","journal-title":"Bol Asoc Med P R"},{"key":"R26A1-12-20210204","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/jcem.86.4.7407","article-title":"Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.","volume":"86","author":"Mazzaferri","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R27A1-12-20210204","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1053-4296(00)80047-8","article-title":"Use of radionuclides for the palliation of bone metastases.","volume":"10","author":"McEwan","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"R29A1-12-20210204","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2265.1999.00635.x","article-title":"Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules.","volume":"50","author":"Nygaard","year":"1999","journal-title":"Clin Endocrinol"},{"key":"R30A1-12-20210204","first-page":"1418","article-title":"Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine.","volume":"35","author":"Pacini","year":"1994","journal-title":"J Nucl Med"},{"key":"R31A1-12-20210204","first-page":"639","article-title":"The role of radioisotopes in radiation oncology.","volume":"24","author":"Park","year":"1997","journal-title":"Semin Oncol"},{"key":"R32A1-12-20210204","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0090-8258(89)90631-8","article-title":"Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.","volume":"32","author":"Potter","year":"1989","journal-title":"Gynecol Oncol"},{"key":"R33A1-12-20210204","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","article-title":"Retention of B-cell-specific monoclonal antibodies by human lymphoma cells.","volume":"83","author":"Press","year":"1994","journal-title":"Blood"},{"key":"R34A1-12-20210204","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","article-title":"A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.","volume":"31","author":"Quilty","year":"1994","journal-title":"Radiother Oncol"},{"key":"R35A1-12-20210204","first-page":"1482","article-title":"A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.","volume":"43","author":"Robbins","year":"2002","journal-title":"J Nucl Med"},{"key":"R36A1-12-20210204","first-page":"44","article-title":"Clinical experience with strontium-89 in prostatic and breast cancer patients.","volume":"20","author":"Robinson","year":"1993","journal-title":"Semin Oncol"},{"key":"R37A1-12-20210204","first-page":"907","article-title":"Outpatient treatment with (131) I anti-B1 antibody: radiation exposure to family members.","volume":"42","author":"Rutar","year":"2001","journal-title":"J Nucl Med"},{"key":"R38A1-12-20210204","first-page":"354","article-title":"A practical methodology for patient release after tositumomab and (131) I-tositumomab therapy.","volume":"43","author":"Siegel","year":"2002","journal-title":"J Nucl Med"},{"key":"R39A1-12-20210204","first-page":"993","article-title":"Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.","volume":"79","author":"Soper","year":"1992","journal-title":"Obstet Gynecol"},{"key":"R40A1-12-20210204","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0002-9378(85)90112-7","article-title":"Intraperitoneal chromic phosphate P32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma.","volume":"153","author":"Soper","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"R41A1-12-20210204","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1148\/radiology.146.2.6849103","article-title":"Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy.","volume":"146","author":"Sullivan","year":"1983","journal-title":"Radiology"},{"key":"R42A1-12-20210204","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/02841869609101653","article-title":"A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system.","volume":"35","author":"Tagesson","year":"1996","journal-title":"Acta Oncol"},{"key":"R43A1-12-20210204","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes.","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"R44A1-12-20210204","article-title":"Nuclear Medicine in Clinical Practice.","author":"Thrall","year":"1982"},{"key":"R45A1-12-20210204","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/1097-0142(19850215)55:4<794::AID-CNCR2820550418>3.0.CO;2-Z","article-title":"Long-term results and prognostic factors in patients with differentiated thyroid carcinoma.","volume":"55","author":"Tubiana","year":"1985","journal-title":"Cancer"},{"key":"R46A1-12-20210204","first-page":"653","article-title":"Diagnostic Nuclear Medicine. 4th ed.","author":"Tuttle","year":"2003"},{"key":"R47A1-12-20210204","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/thy.1999.9.387","article-title":"Short-term effectiveness of low-dose radioiodine ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.","volume":"9","author":"Vermiglio","year":"1999","journal-title":"Thyroid"},{"key":"R48A1-12-20210204","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90) Y-labeled anti-CD20 monoclonal antibody.","volume":"43","author":"Wagner","year":"2002","journal-title":"J Nucl Med"},{"key":"R49A1-12-20210204","first-page":"14S","article-title":"Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.","volume":"39","author":"Wahl","year":"1998","journal-title":"J Nucl Med"},{"key":"R50A1-12-20210204","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from four clinical trials.","volume":"44","author":"Wiseman","year":"2003","journal-title":"J Nucl Med"},{"key":"R51A1-12-20210204","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cncr.10305","article-title":"Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin's lymphoma.","volume":"94","author":"Wiseman","year":"2002","journal-title":"Cancer"},{"key":"R52A1-12-20210204","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"R53A1-12-20210204","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","article-title":"Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials.","volume":"322","author":"Young","year":"1990","journal-title":"N Engl J Med"},{"key":"R54A1-12-20210204","article-title":"Zevalin (ibritumomab tiuxetan) Prescribing Information.","year":"2002"},{"key":"R55A1-12-20210204","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.semnuclmed.2003.11.005","article-title":"Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin).","volume":"34","author":"Zhu","year":"2004","journal-title":"Semin Nucl Med"},{"key":"R56A1-12-20210204","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.semnuclmed.2003.11.001","article-title":"Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).","volume":"34","author":"Zimmer","year":"2004","journal-title":"Semin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003072-201108000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:31:30Z","timestamp":1786044690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003072-201108000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e318224b814","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}